IBBJ:NSD-Defiance Nasdaq Junior Biotechnology ETF (USD)

ETF | Others | NSD

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

N/A

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


IBBJ Stock Forecast & Price:
Based on the Defiance Nasdaq Junior Biotechnology ETF stock forecasts from 0 analysts, the average analyst target price for Defiance Nasdaq Junior Biotechnology ETF is not available over the next 12 months. Defiance Nasdaq Junior Biotechnology ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Defiance Nasdaq Junior Biotechnology ETF is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, Defiance Nasdaq Junior Biotechnology ETF’s stock price was USD 0.00. Defiance Nasdaq Junior Biotechnology ETF’s stock price has changed by 0% over the past week, 0% over the past month and -100.00% over the last year.

No recent analyst target price found for Defiance Nasdaq Junior Biotechnology ETF
No recent average analyst rating found for Defiance Nasdaq Junior Biotechnology ETF

About Defiance Nasdaq Junior Biotechnology ETF (IBBJ:NSD)

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Defiance Nasdaq Junior Biotechnology ETF Allocation
NTLA 3.10 %
BBIO 2.26 %
ZLAB 2.24 %
MEDP 2.15 %
BEAM 2.00 %
KOD 1.92 %
ALLK 1.87 %
TWST 1.86 %
FATE 1.80 %
HALO 1.77 %
Top Sectors

N/A

Top Regions

N/A

Valuation Growth & Performance

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-16 )

Largest Industry Peers for Others

Symbol Name Mer Price(Change) Market Cap
ACWI iShares MSCI ACWI ETF 0.32 %

+0.07 (+0.08%)

USD18.13B
CGABL The Carlyle Group Inc. 4.625% .. 0.00 %

-0.18 (-0.88%)

USD16.14B
CNXCV Concentrix Corporation 0.00 %

N/A

USD4.91B
BUG Global X Cybersecurity ETF 0.50 %

+0.04 (+0.14%)

USD1.11B
TCRX Tscan Therapeutics Inc 0.00 %

-0.22 (-6.53%)

USD0.82B
AGCWW Altimeter Growth Corp 0.00 %

N/A

USD0.74B
ERESW East Resources Acquisition Com.. 0.00 %

-0.02 (-8.33%)

USD0.42B
FREEW FREEW 0.00 %

-0.05 (-13.04%)

USD0.28B
NFIN Netfin Acquisition Corp 0.00 %

N/A

USD0.26B
DSACW Duddell Street Acquisition Cor.. 0.00 %

N/A

USD0.21B

ETFs Containing IBBJ

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Others)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.13% 48% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.13% 44% F 22% F
Risk Return Profile  
Volatility (Standard Deviation) 1.59% 86% B 97% A+
Risk Adjusted Return -8.40% 41% F 19% F
Market Capitalization N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.